Dedicated to the
Development of

A new mechanism of action designed with selectivity and safety in mind.

Ganaxolone, our lead clinical stage drug candidate, brings a new GABAA receptor modulating mechanism and an extensive safety database with exhibited antiepileptic (anti-seizure), anxiolytic (anti-anxiety), and anti-depressive activity.

Our goal is to maximize the value of ganaxolone as a first-in-class innovative neuropsychiatric therapy with a portfolio of diversified indications to treat drug-resistant seizures and neuropsychiatric disorders.